Thank you. Good morning and welcome also on my behalf. We'll start today with the quarter two highlights and a couple of comments on the operating environment and markets. And then I'll end my part with a review of the segments. After this, Timur will take you through the financials before we continue with the question and answer session. In quarter two, we saw good top-line growth, with net sales growing by 13% to €440 million. This was driven by both distribution and wholesale segments. Profitability improved in quarter two. Adjusted EBIT improved by 53% to €5.1 million, while the adjusted EBIT excluding the Swedish dose dispensing business, was €4.9 million. The improvement in profitability was supported by net sales growth, lower operating expenses, and freight costs. We are implementing and rolling out our refined strategy, which was launched at the end of last year. The ERP and warehouse management investment that was kicked off in January has progressed according to plan. At the moment, we are reaching the end of the design phase, which will allow us to move into the build phase during the second half of this year. Something that I have personally also focused quite a lot on during this quarter is engaging with our employees and discussing the strategy and what it means in different parts of the organization. These discussions have been fruitful and, in my opinion, extremely important for creating alignment and commitment to our long-term goals. That is something that we will continue to do. And then finally, a couple of comments on the joint venture company Kronans. Apotekstjänst Sverige AB in quarter two. E-commerce continued to grow steadily, while the brick-and-mortar sector is stabilizing. Kronans Apotek got a new CEO in April and the CFO in May, and they have implemented new measures to improve performance. At the end of April, we announced that the Swedish Competition Authority has prohibited the sale of Svensk dos AB products or services to our protective suites, due to negative effects on market competition. We still think the agreement with Apotekstjänst Sverige AB makes sense and is the most viable option for Oriola, because we have not seen any changes in the market structure and dynamics. We believe that the decision taken by the authorities was not justified and that it was based on weak argumentation. This is why we, together with Apotekstjänst Sverige AB, have appealed the decision. The appeal process can take up to six months, so there will not be news about other alternatives before we have a clear ruling on this. And that will be sometime in early quarter four.
If we take a look at the overall operating environment, we can see that the situation has clearly stabilized from a year back. Consumer confidence has slightly improved, cost inflation has slowed down, and we can see that the energy and fuel prices have stabilized. In the pharmaceutical market environment, there are continuing availability issues across the whole of Europe. We can also see that the demand for high-value pharmaceuticals is at a good level, and this is boosting the value growth in the pharmaceuticals market.
On the other hand, volumes, especially in the finished market, have declined, while in Sweden the volume was still growing at the low single-digit level. As said, the pharmaceutical distribution market's value has continued on a good solid growth in quarter two, which grew about 7% in Sweden and 4% in Finland. In the Finnish market, our market share in quarter two was stable year on year at 45%, and in Sweden we saw a slight decline from 45 to 43%. In the Finnish dose dispensing business, our market share increased by two percentage points to 30%. On this page, you can also see the data from the consumer health market. This is annual data and we will comment on it only on an annual basis.
But as you can see, the historical growth has been at 3% and the market is valued at around €1.5 billion. Let's start then turn and look at how we performed in quarter two. I'll start with the distribution segment, which consists of pharmaceutical logistics and dose dispensing services. In quarter two, net sales grew by 16% to €358 million. This was largely driven by the steady market value growth in Sweden and Finland.
Profitability improved to 30%, with adjusted EBIT increasing to €4.4 million. Profitability improvement was supported by net sales growth and a lower cost base, which has offset the negative impact due to lower volumes in the move and a move of clinical trials under the management of advisory services in wholesale segments. Freight costs were lower thanks to operational improvements, and lower fuel prices, and operating expenses were lower due to cost reductions in the Swedish dose dispensing business. When we exclude the Swedish dose dispensing business, adjusted EBIT was €3.8 million, slightly below last year due to the decline in volume and the move of clinical trials within the EU in the distribution business. We will continue to build on the good development we saw last year in quarter two.
We have been successful in renewing distribution agreements and implementing price increases, which will have a positive impact in the second half. Then, when we're looking at the wholesale segment, the whole segment consists of wholesale of traded goods and over-the-counter or OTC products, parallel import and special licensed medicines, as well as advisory services. In quarter two, net sales in this segment grew by 3% to €82 million, supported by a wider product portfolio in Sweden and growth in all customer segments. Profitability improved to €2.3 million. This is mainly related to the move of clinical trials which I mentioned earlier. Growing the wholesale business is one of our long-term strategic goals. During the start of this year, our focus has been on building our offering and capabilities. For example, we want to grow in the growing e-commerce channel in Sweden, and this has required us to develop certain capabilities in the warehouse in Sweden. This concludes my part. So, over to you, Timo, for the financials.